Who Is Dr. Zhao Weili?
Dr. Zhao Weili (赵维莎) is the Director of the Hematology Department at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine. She is one of China's most distinguished hematologists, internationally recognized for her expertise in lymphoma, leukemia, and other complex blood disorders. Ruijin Hospital's Hematology Department is consistently ranked among the top in China and has a long history of pioneering breakthroughs in blood cancer treatment — including the world-famous "Shanghai Protocol" for acute promyelocytic leukemia (APL).
What Conditions Does She Treat?
Dr. Zhao Weili specializes in the diagnosis and treatment of a wide range of hematological malignancies and blood disorders, including:
- Lymphoma (Hodgkin's and Non-Hodgkin's, including rare subtypes)
- Leukemia (AML, ALL, CML, CLL, APL)
- Multiple myeloma
- Myelodysplastic syndromes (MDS)
- Aplastic anemia and bone marrow failure
- Rare and refractory blood cancers
- CAR-T cell therapy candidacy evaluation
Why International Patients Choose Dr. Zhao
Patients from across Asia, the Middle East, and beyond travel to Shanghai to see Dr. Zhao Weili because Ruijin Hospital's Hematology Department offers treatments and clinical trials that may not be available in their home countries. Dr. Zhao's team is at the forefront of CAR-T cell therapy, targeted therapies, and novel immunotherapy protocols for blood cancers. For patients with relapsed, refractory, or rare hematological conditions, a consultation with Dr. Zhao can open doors to treatment options that are simply not accessible elsewhere.
How CMCS Arranges Your Appointment
Navigating China's top hospitals can be complex — CMCS makes it simple. Here's how we support you:
- Initial Consultation: Contact CMCS and share your diagnosis, pathology reports, bone marrow biopsy results, and treatment history.
- Case Review: Our medical team reviews your case and determines the best approach for a consultation with Dr. Zhao's department.
- Appointment Booking: We coordinate directly with Ruijin Hospital to secure your appointment, including any urgent or priority cases.
- Pre-Visit Preparation: We advise on which records, pathology materials, and imaging to bring or send in advance for review.
- On-the-Day Support: A CMCS coordinator accompanies you through registration, consultation, and any same-day tests or procedures.
- Treatment Coordination: If treatment in Shanghai is recommended, CMCS helps coordinate hospital admission, chemotherapy scheduling, or CAR-T therapy logistics.
What to Prepare Before Your Visit
To ensure the most productive consultation with Dr. Zhao Weili, please prepare:
- Complete pathology and bone marrow biopsy reports (original slides or digital scans preferred)
- Flow cytometry, cytogenetics, and molecular testing results (FISH, PCR, NGS if available)
- Previous treatment records including chemotherapy regimens and response assessments
- Recent blood counts and biochemistry results
- Imaging reports (PET-CT, CT, MRI) if applicable
- A full list of current medications
- Your passport and travel/health insurance documents
What to Expect on the Day
Ruijin Hospital's Hematology Department is a world-class center with deep expertise in complex blood cancers. Your consultation with Dr. Zhao's team will involve a thorough review of your pathology and clinical history, followed by a detailed discussion of diagnosis, prognosis, and treatment options. CMCS will ensure all communication is clear and that you leave with a full understanding of the recommended plan. If additional bone marrow biopsies, molecular testing, or imaging are needed, we can coordinate these efficiently during your time in Shanghai. For patients requiring multidisciplinary input, we can also arrange referrals to other top departments at Ruijin including Oncology and Radiology.
Contact CMCS to Get Started
Ready to book your consultation with Dr. Zhao Weili at Ruijin Hospital? Reach out to our team today:
CMCS is your trusted medical concierge partner in Shanghai — making world-class Chinese healthcare accessible to international patients.
0 comments